JP2010227101A5 - - Google Patents

Download PDF

Info

Publication number
JP2010227101A5
JP2010227101A5 JP2010101904A JP2010101904A JP2010227101A5 JP 2010227101 A5 JP2010227101 A5 JP 2010227101A5 JP 2010101904 A JP2010101904 A JP 2010101904A JP 2010101904 A JP2010101904 A JP 2010101904A JP 2010227101 A5 JP2010227101 A5 JP 2010227101A5
Authority
JP
Japan
Prior art keywords
polynucleotide
crl1005
bak
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010101904A
Other languages
English (en)
Japanese (ja)
Other versions
JP5129292B2 (ja
JP2010227101A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010227101A publication Critical patent/JP2010227101A/ja
Publication of JP2010227101A5 publication Critical patent/JP2010227101A5/ja
Application granted granted Critical
Publication of JP5129292B2 publication Critical patent/JP5129292B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010101904A 2002-12-23 2010-04-27 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン Expired - Fee Related JP5129292B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43554902P 2002-12-23 2002-12-23
US60/435,549 2002-12-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004563851A Division JP2006511221A (ja) 2002-12-23 2003-12-19 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン

Publications (3)

Publication Number Publication Date
JP2010227101A JP2010227101A (ja) 2010-10-14
JP2010227101A5 true JP2010227101A5 (enExample) 2010-12-16
JP5129292B2 JP5129292B2 (ja) 2013-01-30

Family

ID=32682258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004563851A Pending JP2006511221A (ja) 2002-12-23 2003-12-19 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン
JP2010101904A Expired - Fee Related JP5129292B2 (ja) 2002-12-23 2010-04-27 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004563851A Pending JP2006511221A (ja) 2002-12-23 2003-12-19 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン

Country Status (12)

Country Link
US (5) US7410795B2 (enExample)
EP (2) EP2311848B1 (enExample)
JP (2) JP2006511221A (enExample)
AT (1) ATE471335T1 (enExample)
AU (1) AU2003301148A1 (enExample)
CA (2) CA2508228C (enExample)
DE (1) DE60333035D1 (enExample)
DK (1) DK2311848T3 (enExample)
ES (1) ES2429338T3 (enExample)
PT (1) PT2311848E (enExample)
SI (1) SI2311848T1 (enExample)
WO (1) WO2004058166A2 (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) * 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
ES2308069T3 (es) * 1999-03-26 2008-12-01 Vical Incorporated Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas.
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
US7410795B2 (en) 2002-12-23 2008-08-12 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
WO2004060059A2 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US7381422B2 (en) * 2002-12-23 2008-06-03 Vical Incorporated Method for producing sterile polynucleotide based medicaments
EP1607485A1 (en) * 2004-06-14 2005-12-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for quantifying VEGF121 isoform in a biological sample
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
CN1307423C (zh) * 2005-01-08 2007-03-28 王明丽 重组抗原pp65包被酶标反应板的制法及ELISA检测试剂盒
JP2006223194A (ja) * 2005-02-17 2006-08-31 Tosoh Corp スタニオカルシン１（ＳＴＣ１）ｍＲＮＡの測定方法
CA2598884A1 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
EP2366787B1 (en) * 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
US9182398B2 (en) 2006-04-01 2015-11-10 Medical Service Consultation International, Llc Methods and compositions for detecting fungi and mycotoxins
KR101621100B1 (ko) * 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
WO2009005917A2 (en) * 2007-05-29 2009-01-08 Vical Incorporated Methods of treating measles infectious disease in mammals
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
EP3156069B8 (en) 2008-06-20 2020-10-21 Duke University Compositions, methods, and kits for eliciting an immune response
EP2313503A4 (en) * 2008-08-01 2014-01-08 Merck Sharp & Dohme Variant HCMV-PP65, IE1 and IE2 polynucleotides, and uses thereof
US20100068718A1 (en) 2008-08-22 2010-03-18 Hooper Dennis G Methods and Compositions for Identifying Yeast
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US20120164176A1 (en) 2009-07-15 2012-06-28 Kurt Swanson Rsv f protein compositions amd methods for making same
JP5833443B2 (ja) * 2009-08-29 2015-12-16 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
US8962251B2 (en) 2009-10-08 2015-02-24 Medical Service Consultation International, Llc Methods and compositions for identifying sulfur and iron modifying bacteria
CA2779459A1 (en) 2009-10-30 2011-05-05 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
CA2814762A1 (en) * 2010-02-11 2011-08-18 Intelligent Medical Devices, Inc. Oligonucleotides relating to clostridium difficile genes encoding toxin b, toxin a, or binary toxin
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
EP3449910A1 (en) 2010-07-06 2019-03-06 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
LT2590676T (lt) 2010-07-06 2016-10-25 Glaxosmithkline Biologicals Sa Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
US9127321B2 (en) * 2010-10-06 2015-09-08 The Translational Genomics Research Institute Method of detecting Coccidioides species
BR112013008700B8 (pt) 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
EP3527224B1 (en) 2011-01-26 2025-02-26 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
DK3275892T3 (da) 2011-05-13 2020-04-06 Glaxosmithkline Biologicals Sa Præfusions-rsv-f-antigener
EP4043025A1 (en) 2011-06-08 2022-08-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
ES2657547T3 (es) 2011-07-06 2018-03-05 Glaxosmithkline Biologicals Sa Emulsiones aceite en agua que contienen ácidos nucleicos
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
AU2012322704B2 (en) 2011-10-11 2017-09-07 Novartis Ag Recombinant self-replicating polycistronic RNA molecules
CN107875382B (zh) 2011-11-11 2024-03-08 变异生物技术公司 用于治疗巨细胞病毒的组合物和方法
CA2867789C (en) 2012-03-27 2022-06-14 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
JP6199965B2 (ja) 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
CA2897752A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
EP2765137A1 (en) 2013-02-07 2014-08-13 Sanofi Pasteur Induction of cross-reactive cellular response against rhinovirus antigens
BR112015023737A2 (pt) 2013-03-15 2017-10-24 Applied Food Biotech Inc polipeptídeo do receptor felino tas2r isolado (ftas2r), composição, polinucleotídeo isolado, par de iniciadores, vetor de expressão, célula hospedeira, cultura celular, oligonucleotídeo, anticorpo isolado ou um fragmento desse, método para identificar um composto que interage com um polipeptídeo do receptor felino tas2r, método para identificar um composto que modula um polipeptídeo do receptor felino tas2r, método para preparar uma composição comestível, método para formular uma composição comestível com palatabilidade intensificada, método para administrar um composto amargo a um animal que necessita desse, método para preparar uma composição comestível para controlar a palatabilidade da composição comestível para um animal, método para produzir uma composição de sabor para revestimento ou incorporação em uma composição comestível a ser administrada para um animal, e composição de sabor para revestimento ou incorporação em uma composição comestível a ser administrada para um animal
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3110401A4 (en) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
TW201729838A (zh) 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
CA3002922A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2017292010B2 (en) 2016-07-08 2023-07-27 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of disorders and diseases involving RDH12
US20190314486A1 (en) 2016-10-21 2019-10-17 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
ES2978297T3 (es) 2017-05-17 2024-09-10 Massachusetts Gen Hospital Terapia génica para la esclerosis tuberosa
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
JP7541482B2 (ja) 2018-01-29 2024-08-28 メルク・シャープ・アンド・ドーム・エルエルシー 安定化ｒｓｖ ｆタンパク質およびその使用
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN109082413B (zh) * 2018-09-18 2023-01-10 四川安可瑞新材料技术有限公司 抗人IgG单克隆抗体、其杂交瘤细胞株及应用
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CR20220395A (es) 2020-02-14 2022-10-27 Merck Sharp & Dome Llc Vacuna contra hpv
CA3177006A1 (en) 2020-04-27 2022-10-26 University Of Iowa Research Foundation Compositions and methods for the treatment of cystic fibrosis
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
US20230338501A1 (en) 2020-09-04 2023-10-26 Access To Advanced Health Institute Live-attenuated rna hybrid vaccine technology
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
EP4323525A2 (en) 2021-04-16 2024-02-21 Genentech, Inc. Optimized tlr7 ligands and uses thereof
BR112023026258A2 (pt) 2021-06-14 2024-02-27 Bridgebio Gene Therapy Res Inc Terapia genética para esclerose tuberosa
AU2022327583A1 (en) 2021-08-11 2024-02-22 King's College London Compositions and methods for improved treatment of disorders affecting the central nervous system
EP4387660A1 (en) 2021-08-19 2024-06-26 Merck Sharp & Dohme LLC Thermostable lipid nanoparticle and methods of use thereof
WO2023228116A1 (en) 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
EP4583841A1 (en) 2022-09-09 2025-07-16 Access to Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
WO2024068898A1 (en) 2022-09-30 2024-04-04 Centre National De La Recherche Scientifique Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations
WO2024147114A1 (en) 2023-01-06 2024-07-11 Bloomsbury Genetic Therapies Limited Compositions and methods for treating parkinson's disease
TW202509222A (zh) 2023-05-08 2025-03-01 美商默沙東有限責任公司 編碼諾羅病毒vp1抗原之多核苷酸及其用途
US20240408188A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US6133433A (en) 1984-07-27 2000-10-17 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US6242567B1 (en) 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US5124440A (en) 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
JP2607712B2 (ja) 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5837693A (en) 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5721354A (en) * 1995-03-31 1998-02-24 Aviron Human cytomegalovirus DNA sequences
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
US6020481A (en) 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
AU2809897A (en) * 1996-04-23 1997-11-12 Wistar Institute Of Anatomy And Biology, The Novel human cytomegalovirus dna constructs and uses therefor
FR2753512B1 (fr) * 1996-09-19 1998-12-31 Sachs Ind Sa Chaine de transmission notamment pour cycle
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
KR100239879B1 (ko) 1997-11-05 2000-02-01 김상조 간암 예방 및 치료용 생약제
JP3253590B2 (ja) * 1998-08-31 2002-02-04 シャープ株式会社 ハーフトーンマスクの製造方法
ES2308069T3 (es) 1999-03-26 2008-12-01 Vical Incorporated Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas.
FR2804028B1 (fr) 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US6835383B2 (en) * 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
DE60026199T2 (de) 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
US20070092526A1 (en) 2000-06-23 2007-04-26 Evans Robert K Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
US20020110567A1 (en) * 2000-08-10 2002-08-15 Volker Gerdts In utero oral nucleic acid immunization
US7410795B2 (en) * 2002-12-23 2008-08-12 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20050283146A1 (en) 2004-06-17 2005-12-22 Lentz David J Thermally extended spiral cryotip for a cryoablation catheter

Similar Documents

Publication Publication Date Title
JP2010227101A5 (enExample)
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
CN103998604B (zh) Hbv聚合酶突变体
JP2016534034A5 (enExample)
AU2017207764A1 (en) Means and methods for treating HBV
JP2017522907A5 (enExample)
JP2016513115A5 (enExample)
TW201602347A (zh) 對抗腸病毒感染之基於腺病毒載體之疫苗
JP2016513471A5 (enExample)
EP3342866B1 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
KR20200100745A (ko) B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
JP2025084850A (ja) ハンタウイルス抗原性組成物
JP5188400B2 (ja) Ｃ型肝炎ウイルスの非構造融合タンパク質
WO2023089071A1 (en) Vaccine with improved immunogenicity against mutant coronaviruses
CA2795308A1 (en) Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
US20230331782A1 (en) Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease
CA3023706C (en) Adeno-associated virus particle with mutated capsid and methods of use thereof
CN104151402A (zh) 病毒性心肌炎环肽疫苗及其制备方法
CA2996497C (en) Polypeptide carrier for presenting target polypeptide and uses thereof
Liang et al. 3′-UTR sequence of Macrobrachium rosenbergii extra small virus (XSV) is important for viral RNA packaging
CN116888139A (zh) 诱导高水平i型干扰素的新型复制缺陷型甲型流感病毒
JP2014505700A (ja) 抗原性ｇｌｙ１ポリペプチド
US20200261563A1 (en) Cutaneous papilloma virus vaccine